SecBot SecBot
6-K ·Filed Jun 22, 2026

BWAY

Brainsway Ltd.
BULLISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001171843-26-004211
Notable filing: 6-K
Actionable Insight ▲ Bullish

The coverage expansion strengthens the reimbursement runway for SWIFT, supporting future revenue growth. Monitor upcoming quarterly results for evidence of volume acceleration and any competitive responses from alternative TMS or neurostimulation companies.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.38
T+0 close · Jun 22, 2026 · via day close
Latest settled
−6.40%
T+60 · $13.46
Vs SPY
−8.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $14.38entry
  2. T+1 · 5mo ago +0.07%α +1.52% · $14.39
  3. T+5 · 5mo ago +5.49%α +5.95% · $15.17
  4. T+20 · 4mo ago +9.39%α +9.54% · $15.73
  5. T+60 · 2mo ago −6.40%α −8.14% · $13.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay announced expanded favorable insurance coverage for its SWIFT Accelerated Deep TMS protocol, now covering over 57 million covered lives across eight major payers and the VA. This milestone improves reimbursement access and supports future revenue growth.

Key Facts

  • Coverage expanded to over 57 million covered lives for SWIFT Accelerated Deep TMS
  • Eight major payers and the US Department of Veterans Affairs now cover or support accelerated TMS treatment approaches
  • Latest policy change adds 2 million members in South Carolina
  • Follows strong 2025 annual results: 27% revenue growth to $52.2M and net income of $7.6M (per cross-filing 20-F)

Financial Impact

Expanded coverage likely to drive incremental revenue from increased patient access and procedure volumes; no specific revenue impact quantified in filing

revenue

Risk Factors

  • Competing TMS technologies and potential market share erosion
  • Ongoing patent litigation with Magnus Medical as noted in prior annual report
  • Reimbursement changes or delays from additional payers

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-004211
Document: f6k_062126.htm0001171843-26-004211
Document: 0001171843-26-004211-index-headers.html0001171843-26-004211
Document: 0001171843-26-004211-index.html0001171843-26-004211
Document: 0001171843-26-004211.txt0001171843-26-004211

US Market Status

Market Closed · Opens Wed (11h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026